Combining targeted therapy with immunotherapy. Can 1 + 1 equal more than 2?

Seminars in Immunology

Volumn 28, Issue 1, 2016, Pages 73-80

  Robert, Lidia ^a   Ribas, Antoni ^a,b   Hu Lieskovan, Siwen ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adoptive cell transfer; Combination therapy; Immune checkpoint blockade; Targeted therapy

Indexed keywords

ANGIOGENESIS INHIBITOR; HISTONE DEACETYLASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; ANTINEOPLASTIC AGENT; CANCER VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR;

ADOPTIVE TRANSFER; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER STEM CELL; CANCER SURVIVAL; HUMAN; MOLECULARLY TARGETED THERAPY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; TUMOR CELL; TUMOR MICROENVIRONMENT; ADOPTIVE IMMUNOTHERAPY; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; IMMUNOLOGY; MULTIMODALITY CANCER THERAPY; NEOPLASM; PHYSIOLOGY; PROCEDURES;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HISTONE DEACETYLASE INHIBITORS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MOLECULAR TARGETED THERAPY; NEOPLASMS; NEOPLASTIC STEM CELLS; PROTEIN KINASE INHIBITORS; RECEPTOR, ERBB-2; TUMOR MICROENVIRONMENT;

EID: 84964792419     PISSN: 10445323     EISSN: 10963618     Source Type: Journal    
DOI: 10.1016/j.smim.2016.01.001     Document Type: Review

References (102)

1. Clemente C.G., Mihm M.C., Bufalino R., Zurrida S., Collini P., Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996, 77(7):1303-1310.
2. Vesalainen S., Lipponen P., Talja M., Syrjanen K. Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma. Eur. J. Cancer 1994, 30A(12):1797-1803.
3. Leffers N., Gooden M.J., de Jong R.A., Hoogeboom B.N., ten Hoor K.A., Hollema H., et al. Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunol. Immunother. 2009, 58(3):449-459.
4. + T lymphocytes are prognostic factors of human ovarian cancer. Proc. Natl. Acad. Sci. U. S. A. 2007, 104(9):3360-3365.
5. Galon J., Costes A., Sanchez-Cabo F., Kirilovsky A., Mlecnik B., Lagorce-Pages C., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313(5795):1960-1964.
6. Gooden M.J., de Bock G.H., Leffers N., Daemen T., Nijman H.W. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br. J. Cancer 2011, 105(1):93-103.
7. + T cell infiltrations within esophageal carcinomas. Cancer Res. 2001, 61(10):3932-3936.
8. Zhang L., Conejo-Garcia J.R., Katsaros D., Gimotty P.A., Massobrio M., Regnani G., et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 2003, 348(3):203-213.
9. Lu Y.C., Yao X., Crystal J.S., Li Y.F., El-Gamil M., Gross C., et al. Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions. Clin. Cancer Res. 2014, 20(13):3401-3410.
10. Kessler J.H., Beekman N.J., Bres-Vloemans S.A., Verdijk P., van Veelen P.A., Kloosterman-Joosten A.M., et al. Efficient identification of novel HLA-A(*)0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis. J. Exp. Med. 2001, 193(1):73-88.
11. Brichard V., Van Pel A., Wolfel T., Wolfel C., De Plaen E., Lethe B., et al. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 1993, 178(2):489-495.
12. Bakker A.B., Schreurs M.W., de Boer A.J., Kawakami Y., Rosenberg S.A., Adema G.J., et al. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J. Exp. Med. 1994, 179(3):1005-1009.
13. Kawakami Y., Eliyahu S., Sakaguchi K., Robbins P.F., Rivoltini L., Yannelli J.R., et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J. Exp. Med. 1994, 180(1):347-352.
14. McNeil S., Shinde V., Andrew M., Hatchette T., Leblanc J., Ambrose A., et al. Interim estimates of 2013/14 influenza clinical severity and vaccine effectiveness in the prevention of laboratory-confirmed influenza-related hospitalisation, Canada, February 2014. Euro Surveill. 2014, 19(9).
15. Rosenberg S.A., Yang J.C., Sherry R.M., Kammula U.S., Hughes M.S., Phan G.Q., et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 2011, 17(13):4550-4557.
16. Maude S.L., Frey N., Shaw P.A., Aplenc R., Barrett D.M., Bunin N.J., et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 2014, 371(16):1507-1517.
17. Kochenderfer J.N., Wilson W.H., Janik J.E., Dudley M.E., Stetler-Stevenson M., Feldman S.A., et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 2010, 116(20):4099-4102.
18. Chodon T., Comin-Anduix B., Chmielowski B., Koya R.C., Wu Z., Auerbach M., et al. Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma. Clin. Cancer Res. 2014, 20(9):2457-2465.
19. Morgan R.A., Dudley M.E., Wunderlich J.R., Hughes M.S., Yang J.C., Sherry R.M., et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006, 314(5796):126-129.
20. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010, 363(8):711-723.
21. Robert C., Thomas L., Bondarenko I., O'Day S., Weber J., Garbe C., et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 2011, 364(26):2517-2526.
22. Topalian S.L., Hodi F.S., Brahmer J.R., Gettinger S.N., Smith D.C., McDermott D.F., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 2012, 366(26):2443-2454.
23. Hamid O., Robert C., Daud A., Hodi F.S., Hwu W.J., Kefford R., et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 2013, 369(2):134-144.
24. Garon E.B., Rizvi N.A., Hui R., Leighl N., Balmanoukian A.S., Eder J.P., et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 2015, 372(21):2018-2028.
25. Larkin J., Hodi F.S., Wolchok J.D. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 2015, 373(13):1270-1271.
26. Andtbacka R.H., Kaufman H.L., Collichio F., Amatruda T., Senzer N., Chesney J., et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J. Clin. Oncol. 2015, 33(25):2780-2788.
27. Sfaxi F., Scamuffa N., Lalou C., Ma J., Metrakos P., Siegfried G., et al. Repression of liver colorectal metastasis by the serpin Spn4A a naturally occurring inhibitor of the constitutive secretory proprotein convertases. Oncotarget 2014, 5(12):4195-4210.
28. Tsao M.S., Sakurada A., Cutz J.C., Zhu C.Q., Kamel-Reid S., Squire J., et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N. Engl. J. Med. 2005, 353(2):133-144.
29. Shaw A.T., Kim D.W., Nakagawa K., Seto T., Crino L., Ahn M.J., et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N. Engl. J. Med. 2013, 368(25):2385-2394.
30. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 2001, 344(11):783-792.
31. Flaherty K.T., Puzanov I., Kim K.B., Ribas A., McArthur G.A., Sosman J.A., et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 2010, 363(9):809-819.
32. Chapman P.B., Hauschild A., Robert C., Haanen J.B., Ascierto P., Larkin J., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 2011, 364(26):2507-2516.
33. Flaherty K.T., Infante J.R., Daud A., Gonzalez R., Kefford R.F., Sosman J., et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 2012, 367(18):1694-1703.
34. Moriceau G., Hugo W., Hong A., Shi H., Kong X., Yu C.C., et al. Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction. Cancer Cell 2015, 27(2):240-256.
35. Nazarian R., Shi H., Wang Q., Kong X., Koya R.C., Lee H., et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010, 468(7326):973-977.
36. Hugo W., Shi H., Sun L., Piva M., Song C., Kong X., et al. Non-genomic and immune evolution of melanoma acquiring MAPKi resistance. Cell 2015, 162(6):1271-1285.
37. Shi H., Hong A., Kong X., Koya R.C., Song C., Moriceau G., et al. A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition. Cancer Discov. 2014, 4(1):69-79.
38. Shi H., Hugo W., Kong X., Hong A., Koya R.C., Moriceau G., et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov. 2014, 4(1):80-93.
39. Shi H., Moriceau G., Kong X., Lee M.K., Lee H., Koya R.C., et al. Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat. Commun. 2012, 3:724.
40. Ribas A., Wolchok J.D. Combining cancer immunotherapy and targeted therapy. Curr. Opin. Immunol. 2013, 25(2):291-296.
41. Boni A., Cogdill A.P., Dang P., Udayakumar D., Njauw C.N., Sloss C.M., et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res. 2010, 70(13):5213-5219.
42. Frederick D.T., Piris A., Cogdill A.P., Cooper Z.A., Lezcano C., Ferrone C.R., et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin. Cancer Res. 2013, 19(5):1225-1231.
43. Kono M., Dunn I.S., Durda P.J., Butera D., Rose L.B., Haggerty T.J., et al. Role of the mitogen-activated protein kinase signaling pathway in the regulation of human melanocytic antigen expression. Mol. Cancer Res. 2006, 4(10):779-792.
44. Sapkota B., Hill C.E., Pollack B.P. Vemurafenib enhances MHC induction in BRAF homozygous melanoma cells. Oncoimmunology 2013, 2(1):e22890.
45. Acquavella N., Clever D., Yu Z., Roelke-Parker M., Palmer D.C., Xi L., et al. Type I cytokines synergize with oncogene inhibition to induce tumor growth arrest. Cancer Immunol. Res. 2015, 3(1):37-47.
46. Gray-Schopfer V.C., Karasarides M., Hayward R., Marais R. Tumor necrosis factor-alpha blocks apoptosis in melanoma cells when BRAF signaling is inhibited. Cancer Res. 2007, 67(1):122-129.
47. Srividya M.R., Thota B., Shailaja B.C., Arivazhagan A., Thennarasu K., Chandramouli B.A., et al. Homozygous 10q23/PTEN deletion and its impact on outcome in glioblastoma: a prospective translational study on a uniformly treated cohort of adult patients. Neuropathology 2011, 31(4):376-383.
48. Parsa A.T., Waldron J.S., Panner A., Crane C.A., Parney I.F., Barry J.J., et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat. Med. 2007, 13(1):84-88.
49. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304(5676):1497-1500.
50. Akbay E.A., Koyama S., Carretero J., Altabef A., Tchaicha J.H., Christensen C.L., et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 2013, 3(12):1355-1363.
51. Azuma K., Ota K., Kawahara A., Hattori S., Iwama E., Harada T., et al. Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer. Ann. Oncol. 2014, 25(10):1935-1940.
52. Rutledge W.C., Kong J., Gao J., Gutman D.A., Cooper L.A., Appin C., et al. Tumor-infiltrating lymphocytes in glioblastoma are associated with specific genomic alterations and related to transcriptional class. Clin. Cancer Res. 2013, 19(18):4951-4960.
53. Wachowska M., Muchowicz A., Golab J. Targeting epigenetic processes in photodynamic therapy-induced anticancer immunity. Front. Oncol. 2015, 5:176.
54. Feinberg A.P. Phenotypic plasticity and the epigenetics of human disease. Nature 2007, 447(7143):433-440.
55. Jaenisch R., Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat. Genet. 2003, 33(Suppl.):245-254.
56. Li H., Chiappinelli K.B., Guzzetta A.A., Easwaran H., Yen R.W., Vatapalli R., et al. Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers. Oncotarget 2014, 5(3):587-598.
57. Weber J., Salgaller M., Samid D., Johnson B., Herlyn M., Lassam N., et al. Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2'-deoxycytidine. Cancer Res. 1994, 54(7):1766-1771.
58. Coral S., Sigalotti L., Altomonte M., Engelsberg A., Colizzi F., Cattarossi I., et al. 5-Aza-2'-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications. Clin. Cancer Res. 2002, 8(8):2690-2695.
59. Sigalotti L., Fratta E., Coral S., Maio M. Epigenetic drugs as immunomodulators for combination therapies in solid tumors. Pharmacol. Ther. 2014, 142(3):339-350.
60. Wanczyk M., Roszczenko K., Marcinkiewicz K., Bojarczuk K., Kowara M., Winiarska M. HDACi - going through the mechanisms. Front. Biosci. (Landmark Ed.) 2011, 16:340-359.
61. Van den Eynde B.J., Boon T. Tumor antigens recognized by T lymphocytes. Int. J. Clin. Lab. Res. 1997, 27(2):81-86.
62. Guo Z.S., Hong J.A., Irvine K.R., Chen G.A., Spiess P.J., Liu Y., et al. De novo induction of a cancer/testis antigen by 5-aza-2'-deoxycytidine augments adoptive immunotherapy in a murine tumor model. Cancer Res. 2006, 66(2):1105-1113.
63. + T cells on the surface of malignant pleural mesothelioma cells treated with HDACi. Eur. J. Immunol. 2012, 42(3):783-789.
64. Woods D.M., Woan K., Cheng F., Wang H., Perez-Villarroel P., Lee C., et al. The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity. Melanoma Res. 2013, 23(5):341-348.
65. Gregorie C.J., Wiesen J.L., Magner W.J., Lin A.W., Tomasi T.B. Restoration of immune response gene induction in trophoblast tumor cells associated with cellular senescence. J. Reprod. Immunol. 2009, 81(1):25-33.
66. Yang H., Bueso-Ramos C., DiNardo C., Estecio M.R., Davanlou M., Geng Q.R., et al. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia 2014, 28(6):1280-1288.
67. Woods D.M., Sodre A.L., Villagra A., Sarnaik A., Sotomayor E.M., Weber J. HDAC inhibition upregulates PD-1 ligands in melanoma and augments immunotherapy with PD-1 blockade. Cancer Immunol. Res. 2015, 3(December (12)):1375-1385. 10.1158/2326-6066.CIR-15-0077-T.
68. Kim K., Skora A.D., Li Z., Liu Q., Tam A.J., Blosser R.L., et al. Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. Proc. Natl. Acad. Sci. U. S. A. 2014, 111(32):11774-11779.
69. Su F., Viros A., Milagre C., Trunzer K., Bollag G., Spleiss O., et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N. Engl. J. Med. 2012, 366(3):207-215.
70. Koya R.C., Mok S., Otte N., Blacketor K.J., Comin-Anduix B., Tumeh P.C., et al. BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy. Cancer Res. 2012, 72(16):3928-3937.
71. Comin-Anduix B., Chodon T., Sazegar H., Matsunaga D., Mock S., Jalil J., et al. The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations. Clin. Cancer Res. 2010, 16(24):6040-6048.
72. Hong D.S., Vence L., Falchook G., Radvanyi L.G., Liu C., Goodman V., et al. BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency. Clin. Cancer Res. 2012, 18(8):2326-2335.
73. Knight D.A., Ngiow S.F., Li M., Parmenter T., Mok S., Cass A., et al. Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J. Clin. Investig. 2013, 123(3):1371-1381.
74. Vella L.J., Pasam A., Dimopoulos N., Andrews M., Knights A., Puaux A.L., et al. MEK inhibition, alone or in combination with BRAF inhibition, affects multiple functions of isolated normal human lymphocytes and dendritic cells. Cancer Immunol. Res. 2014, 2(4):351-360.
75. Hu-Lieskovan S., Mok S., Homet Moreno B., Tsoi J., Robert L., Goedert L., et al. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. Sci. Transl. Med. 2015, 7(279):279ra41.
76. Homet Moreno B., Mok S., Comin-Anduix B., hu-Lieskovan S., Ribas A. Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma. Oncoimmunology 2015, 10.1080/2162402X.2015.1052212.
77. Long G.V., Wilmott J.S., Haydu L.E., Tembe V., Sharma R., Rizos H., et al. Effects of BRAF inhibitors on human melanoma tissue before treatment, early during treatment, and on progression. Pigment Cell Melanoma Res. 2013, 26(4):499-508.
78. Cooper Z.A., Frederick D.T., Juneja V.R., Sullivan R.J., Lawrence D.P., Piris A., et al. BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes. Oncoimmunology 2013, 2(10):e26615.
79. Tumeh P.C., Harview C.L., Yearley J.H., Shintaku I.P., Taylor E.J., Robert L., et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014, 515(7528):568-571.
80. + T cells. Sci. Transl. Med. 2013, 5(200):200ra116.
81. Cooper Z.A., Juneja V.R., Sage P.T., Frederick D.T., Piris A., Mitra D., et al. Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade. Cancer Immunol. Res. 2014, 2(7):643-654.
82. Crompton J.G., Sukumar M., Roychoudhuri R., Clever D., Gros A., Eil R.L., et al. Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics. Cancer Res. 2015, 75(2):296-305.
83. Vaziri K., Roland J.C., Robinson L.L., Reines H.D., Fakhry S.M. Extreme anemia in an injured Jehovah's Witness: a test of our understanding of the physiology of severe anemia and the threshold for blood transfusion. J. Trauma 2009, 67(1):E11-E13.
84. Luo M., Fan H., Nagy T., Wei H., Wang C., Liu S., et al. Mammary epithelial-specific ablation of the focal adhesion kinase suppresses mammary tumorigenesis by affecting mammary cancer stem/progenitor cells. Cancer Res. 2009, 69(2):466-474.
85. Pachter J.A., Kolev V.N., Schunselaar L., Shapiro I.M., Bueno R., Baas P., et al. FAK inhibitor VS-6063 (defactinib) targets mesothelioma cancer stem cells, which are enriched by standard of care chemotherapy. American Association for Cancer Research, Poster 2015.
86. Stokes J.B., Adair S.J., Slack-Davis J.K., Walters D.M., Tilghman R.W., Hershey E.D., et al. Inhibition of focal adhesion kinase by PF-562,271 inhibits the growth and metastasis of pancreatic cancer concomitant with altering the tumor microenvironment. Mol. Cancer Ther. 2011, 10(11):2135-2145.
87. Ring J., Li Y., Shapiro I.M., Wang Y., Weaver D.T., Pachter J.A. FAK/PYK2 inhibitors defatinib and VS-4718 enhance immune checkpoint inhibitor efficacy. SITC Poster 2015 2015.
88. Sumimoto H., Imabayashi F., Iwata T., Kawakami Y. The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J. Exp. Med. 2006, 203(7):1651-1656.
89. Larkin J., Chiarion-Sileni V., Gonzalez R., Grob J.J., Cowey C.L., Lao C.D., et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 2015, 373(1):23-34.
90. Khalili J.S., Liu S., Rodriguez-Cruz T.G., Whittington M., Wardell S., Liu C., et al. Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma. Clin. Cancer Res. 2012, 18(19):5329-5340.
91. Liu C., Peng W., Xu C., Lou Y., Zhang M., Wargo J.A., et al. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin. Cancer Res. 2013, 19(2):393-403.
92. Nicholson A.M., Ledgister S., Williams T., Robinson S., Gayle P., Lindo T., et al. Distribution of nosocomial organisms and their resistance patterns in the intensive care unit of the University Hospital of the West Indies, Kingston, Jamaica. West Indian Med. J. 2009, 58(2):142-148.
93. Balachandran V.P., Cavnar M.J., Zeng S., Bamboat Z.M., Ocuin L.M., Obaid H., et al. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat. Med. 2011, 17(9):1094-1100.
94. Ozao-Choy J., Ma G., Kao J., Wang G.X., Meseck M., Sung M., et al. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res. 2009, 69(6):2514-2522.
95. Minor D.R., Puzanov I., Callahan M.K., Hug B.A., Hoos A. Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab. Pigment Cell Melanoma Res. 2015, 28(5):611-612.
96. Collins D.M., O'Donovan N., McGowan P.M., O'Sullivan F., Duffy M.J., Crown J. Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines. Ann. Oncol. 2012, 23(7):1788-1795.
97. Ming Lim C., Stephenson R., Salazar A., Ferris R. TLR3 agonists improve the immunostimulatory potential of cetuximab against EGFR+ head and neck cancer cells. Oncoimmunology 2013, 2:e24677. 10.4161/onci.24677.
98. Amin A. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC). ASCO 2014 2014.
99. Rini B.I., Stein M., Shannon P., Eddy S., Tyler A., Stephenson J.J., et al. Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma. Cancer 2011, 117(4):758-767.
100. Juergens R.A., Wrangle J., Vendetti F.P., Murphy S.C., Zhao M., Coleman B., et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov. 2011, 1(7):598-607.
101. Wrangle J., Wang W., Koch A., Easwaran H., Mohammad H.P., Vendetti F., et al. Alterations of immune response of non-small cell lung cancer with azacytidine. Oncotarget 2013, 4(11):2067-2079.
102. Munster P.N., Thurn K.T., Thomas S., Raha P., Lacevic M., Miller A., et al. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br. J. Cancer 2011, 104(12):1828-1835.